ADMA Biologics Inc (NASDAQ:ADMA) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.50.

A number of equities research analysts have commented on ADMA shares. Oppenheimer set a $13.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Wednesday, September 5th. LADENBURG THALM/SH SH reduced their price objective on shares of ADMA Biologics to $7.50 and set a “buy” rating for the company in a report on Wednesday, June 13th. Maxim Group lifted their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, July 26th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Finally, Chardan Capital initiated coverage on shares of ADMA Biologics in a report on Monday, July 30th. They set a “buy” rating and a $10.00 price objective for the company.

Several hedge funds and other institutional investors have recently modified their holdings of ADMA. Millennium Management LLC grew its holdings in shares of ADMA Biologics by 254.0% during the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 48,455 shares during the last quarter. BlackRock Inc. boosted its holdings in ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares during the last quarter. Spark Investment Management LLC purchased a new position in ADMA Biologics during the first quarter worth about $102,000. JPMorgan Chase & Co. purchased a new position in ADMA Biologics during the first quarter worth about $182,000. Finally, Element Capital Management LLC purchased a new position in ADMA Biologics during the first quarter worth about $118,000. Hedge funds and other institutional investors own 56.38% of the company’s stock.

NASDAQ:ADMA opened at $6.46 on Tuesday. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $290.14 million, a price-to-earnings ratio of -3.38 and a beta of 2.35. ADMA Biologics has a 12 month low of $2.01 and a 12 month high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $4.66 million during the quarter, compared to analyst estimates of $5.35 million. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. research analysts anticipate that ADMA Biologics will post -1.31 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.